Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.02 CAD | -3.81% | -6.48% | -25.19% |
Apr. 17 | NervGen Reports FY 2023 Net Loss of $0.38 Per Share, Provides Operations Update | MT |
Apr. 17 | NervGen Pharma Corp. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Sales 2024 * | - | Sales 2025 * | - | Capitalization | 141M 103M |
---|---|---|---|---|---|
Net income 2024 * | - | Net income 2025 * | - | EV / Sales 2024 * | - |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-
| P/E ratio 2025 * |
-
| Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 77.07% |
1 day | -3.81% | ||
1 week | -6.48% | ||
Current month | -3.81% | ||
1 month | -3.35% | ||
3 months | -44.20% | ||
6 months | +12.22% | ||
Current year | -25.19% |
Managers | Title | Age | Since |
---|---|---|---|
William Radvak
FOU | Founder | 61 | 17-01-18 |
Michael Kelly
CEO | Chief Executive Officer | 59 | 23-04-09 |
Bill Adams
DFI | Director of Finance/CFO | 62 | 20-02-23 |
Members of the board | Title | Age | Since |
---|---|---|---|
Randall Kaye
BRD | Director/Board Member | 61 | 20-10-27 |
Brian Bayley
BRD | Director/Board Member | 71 | 18-05-15 |
William Radvak
FOU | Founder | 61 | 17-01-18 |
Date | Price | Change | Volume |
---|---|---|---|
24-05-09 | 2.02 | -3.81% | 22,400 |
24-05-08 | 2.1 | +3.96% | 71,398 |
24-05-07 | 2.02 | -3.81% | 260,992 |
24-05-06 | 2.1 | -9.87% | 176,958 |
24-05-03 | 2.33 | +7.87% | 261,878 |
Delayed Quote Toronto S.E., May 09, 2024 at 03:59 pm EDT
More quotesQuarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-25.19% | 103M | |
+23.37% | 47.02B | |
+49.51% | 41.86B | |
-0.94% | 41.76B | |
-4.32% | 28.8B | |
+11.29% | 26.05B | |
-20.92% | 19.15B | |
+3.20% | 12.55B | |
-2.67% | 11.82B | |
+30.23% | 12.34B |
- Stock Market
- Equities
- NGEN Stock